<DOC>
	<DOCNO>NCT02151734</DOCNO>
	<brief_summary>This multi-center , double-dummy , double-blind , randomize , active-controlled , parallel group phase 3 clinical trial evaluate efficacy safety KALOMIN™ Tab . patient acute bronchitis . The aim clinical trial demonstrate KALOMIN™ Tab . clinically non-inferior Umckamin syrup , assess BSS ( Bronchitis Severity Score ) , treatment acute bronchitis 7 day .</brief_summary>
	<brief_title>Safety Efficacy KALOMIN™ Tab . Patients With Acute Bronchitis</brief_title>
	<detailed_description />
	<mesh_term>Bronchitis</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<criteria>Male female patient age 1275 year old A total score BSS ≥ 5 The duration symptoms less 14 day chronic pulmonary disease Patients voluntarily sign write informed consent participate trial Indication antibiotic treatment ( e.g . severe respiratory infection ) Allergic bronchial asthma Tendency bleed Severe heart , renal , liver disease decline immune function Chronic obstructive pulmonary disease Known suppose hypersensitivity investigational medication Treatment antibiotic past 4 week prior inclusion trial Women pregnancy lactation period Clinically significant abnormal value screen test ( twice upper limit normal range ALT , AST , BUN , Serum Creatinine ) Participation trial within 30 day prior inclusion trial Unsuitable patient enrollment opinion investigator</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>